Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study

Pan, Rubing; Zhang, Xulai; Gao, Jiaqi; Yi, Weizhuo; Wei, Qiannan; Su, Hong

doi:10.1016/j.psychres.2020.113260

Cited by 32 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pooled estimate showed a significant decrease in patients with a small effect size (standardized mean difference [SMD] = −0.26; 95% CI, −0.47 to −0.06; P = .01) and high heterogeneity ( I 2 = 75%) ( Figure 1 A). 3 , 4 , 22 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 Within diagnostic categories, there was a significant decrease only in bipolar disorder (SMD = −0.61; 95% CI, −1.19 to −0.03; P = .04; I 2 = 80%). Twenty-six studies provided data on Chao1 in patients (n = 956) vs controls (n = 961).…”

Section: Resultsmentioning

confidence: 96%

“…Regarding individual diagnoses, there was a significant decrease only in bipolar disorder and anorexia nervosa (SMD = −0.53; 95% CI, −1.01 to −0.05; P = .03; I 2 = 62% and SMD = −0.86; 95% CI, −1.52 to −0.21; P = .01; I 2 = 80%, respectively) ( Figure 1 B). 4 , 21 , 25 , 27 , 29 , 31 , 32 , 33 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Perturbations in Gut Microbiota Composition in Psychiatric Disorders

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

Perturbations in Gut Microbiota Composition in Psychiatric Disorders

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Altered metabolic pathways have, in turn, been associated with inflammatory cytokines and risk for coronary heart disease in psychosis and schizophrenia. This has been replicated in animal studies with specific behavioural patterns [44][45][46][47][48] . Changes in microbiota composition have also been identified as potential biomarkers for psychosis and schizophrenia that might aid in diagnosis.…”

Section: Discussionmentioning

confidence: 67%

Compositional and functional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia: A systematic review

et al. 2021

View full text Add to dashboard Cite

Background: Gut and oral microbiota are intrinsically linked to human health. Recent studies suggest a direct link with mental health through bidirectional gut–brain pathways. Emerging evidence suggests that the composition and/or function of intestinal microbiome differs in those with psychosis and schizophrenia as compared with controls. There is relatively little research on the predicted or actual functional alterations associated with the composition of oral and gut microbiota in patients with psychosis. We will perform a systematic review and meta-analysis to identify, evaluate and if possible, combine the published literature on compositional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia compared with healthy controls. We also aim to explore the potential functional impact of any compositional changes. Methods: Original studies involving humans and animals using a case-control, cohort or cross-sectional design will be included. The electronic databases PsycINFO, EMBASE, Web of Science, PubMed/MEDLINE and Cochrane will be systematically searched. Quantitative analyses will be performed using random-effects meta-analyses to calculate mean difference with 95% confidence intervals. Discussion: Changes in microbiota composition in psychosis and schizophrenia have been correlated with alternations in brain structure and function, altered immunity, altered metabolic pathways and symptom severity. Changes have also been identified as potential biomarkers for psychosis that might aid in diagnosis. Understanding how predicted or actual functional alterations in microbial genes or metabolic pathways influence symptomatic expression and downstream clinical outcomes may contribute to the development of microbiome targeted interventions for psychosis. Registration: The study is prospectively registered in PROSPERO, the International Prospective Register of Systematic Reviews (CRD42021260208).

show abstract

“…Genus analysis has shown that some genera from Firmicutes showed lower levels in SCH patients than in HCs, such as Blautia , Coprococcus , Roseburia , Blautia , Streptococcus , Enterococcus [ 12 , 13 ]; other genera from Firmicutes , including Megasphaera , Lactobacillus , and Clostridium , were enriched in SCH [ 12 , 13 ]. In addition, several genera from the phyla Proteobacteria [ 12 ] (e.g., Succinivibrio , and Klebsiella ) and Actinobacteria [ 9 , 12 , 18 , 19 ] (e.g., Collinsella , Actinomyces , and Eggerthella ) showed higher levels in SCH patients. Albeit inconsistent associations for specific microbial taxa, these studies indicated that patients with SCH displayed a dysbiosis of gut microbiota.…”

Section: Introductionmentioning

confidence: 99%

Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study

Yuan

Wang

et al. 2021

Transl Psychiatry

View full text Add to dashboard Cite

Preclinical studies have shown that the gut microbiota can play a role in schizophrenia (SCH) pathogenesis via the gut-brain axis. However, its role in the antipsychotic treatment response is unclear. Here, we present a 24-week follow-up study to identify gut microbial biomarkers for SCH diagnosis and treatment response, using a sample of 107 first-episode, drug-naïve SCH patients, and 107 healthy controls (HCs). We collected biological samples at baseline (all participants) and follow-up time points after risperidone treatment (SCH patients). Treatment response was assessed using the Positive and Negative Symptoms Scale total (PANSS-T) score. False discovery rate was used to correct for multiple testing. We found that SCH patients showed lower α-diversity (the Shannon and Simpson’s indices) compared to HCs at baseline (p = 1.21 × 10−9, 1.23 × 10−8, respectively). We also found a significant difference in β-diversity between SCH patients and HCs (p = 0.001). At baseline, using microbes that showed different abundance between patients and controls as predictors, a prediction model can distinguish patients from HCs with an area under the curve (AUC) of 0.867. In SCH patients, after 24 weeks of risperidone treatment, we observed an increase of α-diversity toward the basal level of HCs. At the genus level, we observed decreased abundance of Lachnoclostridium (p = 0.019) and increased abundance Romboutsia (p = 0.067). Moreover, the treatment response in SCH patients was significantly associated with the basal levels of Lachnoclostridium and Romboutsia (p = 0.005 and 0.006, respectively). Our results suggest that SCH patients may present characteristic microbiota, and certain microbiota biomarkers may predict treatment response in this patient population.

show abstract

Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study

Cited by 32 publications

References 28 publications

Perturbations in Gut Microbiota Composition in Psychiatric Disorders

Perturbations in Gut Microbiota Composition in Psychiatric Disorders

Compositional and functional alterations in the oral and gut microbiota in patients with psychosis or schizophrenia: A systematic review

Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study

Contact Info

Product

Resources

About